Explore healthcare trends, quizzes, tips, web stories, and medical humor in our weekly newsletter, Volume No.4, Issue No.10 ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for la ...

Executives from Oric Pharmaceuticals (NASDAQ:ORIC) used a conference discussion to highlight near-term clinical catalysts for its two lead oncology programs and to outline how upcoming data could ...

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial ResultsFourth quarter revenue growth of 19% to $29.5 million2025 revenue growth ...

The fourth quarter follows a strong third-quarter performance when Veracyte beat expectations on both earnings and revenue, posting a 59% EPS surprise. The company preannounced preliminary ...

Vir Biotechnology Inc (VIR) reports reduced expenses and a promising collaboration with Estelas, setting the stage for future growth.

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...